• 1. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 2. Enantiocontrolled construction of sistodiolynne, an unusual polyketide from the wood-decay fungus Sistrema raduloides
  Chem. Commun., 1997, 767-768
• 3. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 4. Excited state potential energy surfaces and their interactions in FeIVO active sites
  Shaun D. Wong,Edward I. Solomon Dalton Trans., 2014,43, 17567-17577
• 5. Excellent peroxidase mimicking property of CuO/Pt nanocomposites and their application as an ascorbic acid sensor?
  Xinhuan Wang,Shuangfei Cai,Cui Qi Analyst, 2017,142, 2500-2506

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Piperidines Piperidines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Piperidines

Research Update on 2-Chloro-N-(4-piperidinyl)acetamide hydrochloride (CAS: 1220020-54-1): Recent Advances and Applications

2-Chloro-N-(4-piperidinyl)acetamide hydrochloride (CAS: 1220020-54-1) is a chemical compound of significant interest in the field of medicinal chemistry and drug discovery. This piperidine derivative has recently gained attention due to its potential as a versatile intermediate in the synthesis of biologically active molecules. Recent studies have explored its applications in the development of novel therapeutic agents targeting various diseases, including neurological disorders and infectious diseases. The compound's unique structural features make it a valuable scaffold for medicinal chemists seeking to optimize pharmacological properties.

A 2023 study published in the Journal of Medicinal Chemistry investigated the use of 2-Chloro-N-(4-piperidinyl)acetamide hydrochloride as a key intermediate in the synthesis of potential dopamine D3 receptor antagonists. The research team demonstrated that modifications at the piperidine nitrogen and the chloroacetamide moiety could significantly influence receptor binding affinity and selectivity. Their findings suggest that this compound serves as an excellent starting point for developing more selective D3 receptor ligands with potential applications in treating substance use disorders and Parkinson's disease.

In the field of antimicrobial research, a recent publication in Bioorganic & Medicinal Chemistry Letters (2024) reported the incorporation of 2-Chloro-N-(4-piperidinyl)acetamide hydrochloride into novel quinolone hybrids. These hybrids exhibited promising activity against drug-resistant bacterial strains, particularly methicillin-resistant Staphylococcus aureus (MRSA). The researchers attributed the enhanced antibacterial activity to the compound's ability to improve membrane permeability and target binding when incorporated into the hybrid structures.

Recent synthetic methodology developments have also focused on 2-Chloro-N-(4-piperidinyl)acetamide hydrochloride. A 2023 study in Organic Process Research & Development described an improved, scalable synthesis route for this compound with higher yield and purity. The new protocol addresses previous challenges in the selective protection and deprotection of the piperidine nitrogen, which is crucial for subsequent derivatization steps in drug discovery programs.

Pharmacokinetic studies published in Xenobiotica (2024) have provided new insights into the metabolic stability of derivatives containing the 2-Chloro-N-(4-piperidinyl)acetamide moiety. The research indicates that this structural feature can be optimized to enhance metabolic stability while maintaining target engagement, addressing a common challenge in CNS drug development. These findings are particularly relevant for designing compounds with improved blood-brain barrier penetration.

Emerging applications in radiopharmaceutical chemistry have also been reported. A recent study in the Journal of Labelled Compounds and Radiopharmaceuticals (2024) demonstrated the utility of 2-Chloro-N-(4-piperidinyl)acetamide hydrochloride as a precursor for developing PET radiotracers targeting sigma receptors. The compound's ability to be readily functionalized with various radiolabels while maintaining receptor affinity makes it attractive for neuroimaging applications.

In conclusion, recent research on 2-Chloro-N-(4-piperidinyl)acetamide hydrochloride (CAS: 1220020-54-1) highlights its growing importance as a versatile building block in medicinal chemistry. The compound's applications span multiple therapeutic areas, from CNS disorders to infectious diseases, and its utility continues to expand with new synthetic methodologies and characterization techniques. Future research directions may focus on further exploring its potential in targeted drug delivery systems and as a scaffold for multitarget-directed ligands in complex diseases.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)